Navigation Links
Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
Date:10/20/2009

id in the development of future clinical studies. We are grateful to the Juvenile Diabetes Research Foundation for their support and funding of our studies using this promising endpoint."

Details of Presentation of IENFD Data from SB-509-601 Study

Tuesday, October 20, 2009

  • "Epidermal nerve fiber density and regeneration with vascular endothelial growth factor zinc finger protein activator (SB-509) in mild to moderate diabetic peripheral neuropathy patients. (SB-509-0601 study)." M. Polydefkis(1), P. Haurei(1), *E. Benaim(2), D. Ando(2), S. Hamilton(2), H. Kim(2), S. Study Group(2); (1) Johns Hopkins Univ., Baltimore, MD; (2) Clin. Affairs, Sangamo BioSciences, Richmond, CA

IENFD and IENFD Regrowth (IENFDR) measurements were prospectively defined endpoints in Sangamo's double-blind, repeat dosing Phase 2 clinical study (SB-509-601) in which subjects were treated at 0, 60 and 120 days. Evaluation of SB-509 treatment on IENFD and IENFDR was carried out in collaboration with Michael Polydefkis, M.D., Associate Professor of Neurology, Johns Hopkins University Medical School and funded by a grant from the Juvenile Diabetes Research Foundation (JDRF).

IENFD derived from 3mm skin punch biopsies taken from the thigh at baseline (Day 0) and thirty days after the final treatment (Day 150) were obtained from both SB-509 and placebo treated subjects. In addition, IENFDR was determined by applying a capsaicin patch to the skin of the thigh to produce a standardized nerve injury on Days 150 and 151 and using serial skin biopsies over time, post capsaicin treatment, up to Day 360, to determine nerve regrowth in both SB-509 and placebo-treated subjects.

In SB-509 treated subjects an increase in mean change in nerve fiber density from baseline was observed compared to a decrease for placebo treated subjects (p-value = 0.02). Importantly, a rank sum analysis of these data
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
2. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
5. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
6. Magellan Biosciences Sells its Life Sciences Tools Business to Dionex
7. Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System
8. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
9. Cell Biosciences Launches Unique Protein Phosphorylation Assay Service
10. Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences(R) to Provide World-Class Fluid Management and Liquid/Powder System Solutions
11. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... (PRWEB) March 06, 2015 Follow ... as the pharmacokinetics of a drug refers to testing ... compound inside an organism. When toxicity studies are clubbed ... ADMET or ADME/Tox. Increasing focus on lowering costs and ... ADME-toxicology testing worldwide. The traditional drug development model uses ...
(Date:3/6/2015)... CHICAGO (PRWEB) March 06, 2015 As ... and healthcare services programs, the organization has hired two ... Hagerty, Ph.D. They will report to Grace Pavlath, ... Vice President and Scientific Program Director, and together will ... lead to treatments and cures for various types of ...
(Date:3/6/2015)... “On Tap” takes the audience on a journey ... the silver screen and to modern day rhythm tap. ... their famous eye-high kicks! Producers, directors and choreographers Mary Six ... dancing in this robust show, showcasing one of the only ... , “On Tap” is proud to host guest stars ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 US Sports ... three Maryland camps – two non-contact specialty camps and ... run by Perfect Performance Training, located at Bowie State ... on developing position specific skills, speed and strength of ... at Salisbury University with Marvin Graves, former quarterback in ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
Breaking Medicine News(10 mins):Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3
... Honda Motor Co., Ltd. will showcase an,experimental model of ... elderly and other people with weakened leg muscles, at ... for,the Elderly & the Disabled (BARRIER FREE 2008) which ... Sunday, April 27, 2008., (Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU095A ), ...
... surgeries has declined, so has death rate, study ... that perform fewer cardiac bypass operations don,t have more ... greater number of bypasses, a new study says. , ... hospitals that do more cardiac bypass operations have better ...
... Select Medical,Corporation, a leading provider of specialty ... $2.6 million gift to Harrisburg,University of Science and ... investment by a corporation in,the six-year history of ... Corporation Conference Center in the University,s new 16-story,Academic ...
... an experience many people describe as stressful and uncomfortable, ... the work of a team of University of Florida ... that shows promise of reducing the extremely loud, repetitive, ... noises, which range from beeping to whirring to grinding ...
... 22 For a limited time, Perr&Knight,is offering ... who are,interested in obtaining their competitors, rate, rule ... RateFilings.com., RateFilings.com features hundreds of thousands of ... and every business day we add several,hundred recent ...
... stent will be featured at a sponsored symposium during Angioplasty ... place on April 23 at the Convention,Center of Sheraton Grande ... -- "Opening Address" by Seung-Jung Park, the symposium,s chairperson, ... "Endothelial Progenitor Cell Capture Technology and Beyond" by Michael ...
Cached Medicine News:Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 2Health News:Quality Care, Not Number of Procedures, Determines Bypass Results 3Health News:Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University 2Health News:Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University 3Health News:Engineering students: Headset muffles loud, unnerving MRI noises 2Health News:Engineering students: Headset muffles loud, unnerving MRI noises 3Health News:Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2
(Date:3/6/2015)... March 6, 2015 Ultra Clean ... Intuitive Surgical, the manufacturer of da Vinci® ... Cleaning System. This approval reflects the unit,s ability ... currently in place for the sterile processing industry. ... reprocessing robotic surgical instruments for re-use. ...
(Date:3/6/2015)... 2015  The German Court of Appeal has ruled that ... regimen patent for Alimta® (pemetrexed disodium) would not be infringed ... salt form of pemetrexed in Germany ... The German Court ruled in favor of the generic ... Actavis. This decision vacated the prior decision of the Regional ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 3TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows ... and Pulmonary,Embolism Compared with Enoxaparin with Similarly ... - Late-breaking Phase III clinical trial,data presented ... Thrombosis,and Haemostasis (ISTH) Congress demonstrate that once-daily,rivaroxaban ...
... Massachusetts, July 08, 2007 /PRNewswire/ -- , ... to Urgently,Implement Hospital-Wide Strategies to Optimize VTE ... Provide Appropriate,prophylaxis to Prevent VTE , Venous ... and most of these at-risk patients are ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: